الصفحة الرئيسية>>Signaling Pathways>> PROTAC>>Docosanedioic acid

Docosanedioic acid

رقم الكتالوجGC64199

حمض Docosanedioic هو رابط ADC غير قابل للكسر يستخدم في تخليق اتحادات الأجسام المضادة والأدوية (ADCs)حمض Docosanedioic هو أيضًا رابط PROTAC قائم على سلسلة ألكيل يمكن استخدامه في تخليق PROTACs

Products are for research use only. Not for human use. We do not sell to patients.

Docosanedioic acid التركيب الكيميائي

Cas No.: 505-56-6

الحجم السعر المخزون الكميّة
100 mg
45٫00
متوفر
250 mg
81٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

مراجعات

Review for Docosanedioic acid

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Docosanedioic acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.